Department of Gastroenterology, The First Affiliated Hospital, Anhui Medical University, Hefei 230022, PR China.
Oncol Rep. 2011 Apr;25(4):1047-52. doi: 10.3892/or.2011.1170. Epub 2011 Jan 31.
The aim of this study was to investigate the relationship between the ERCC1-C8092A, ERCC1-C19007T and GSTP1-A105G genetic polymorphisms and the curative effect of cisplatin-based chemotherapy in advanced esophageal carcinoma. A total of 256 pathologically confirmed advanced esophageal carcinoma patients were given regimens of cisplatin and 5-fluorouracil. Clinical evaluations were obtained from 241 patients who completed the therapy. The remission rate of patients with ERCC1-C8092A, A/C or A/A was higher compared to that of patients with C/C (51.75 vs. 29.59%, P<0.01). Progression-free survival of patients with ERCC1-C8092A, A/C or A/A was longer compared to that of patients with C/C (7.5 months vs. 4.5 months, P<0.0001). The C19007T and GSTP1-A105G genetic polymorphisms were not positively correlated with remission rates and progression-free survival of patients. In conclusion, the ERCC1-C8092A genetic polymorphism may be correlated with the efficacy of cisplatin-based chemotherapy in cases of advanced esophageal carcinoma. Further studies with a larger sample size are needed for tailored chemotherapy treatment of advanced esophageal carcinoma.
本研究旨在探讨 ERCC1-C8092A、ERCC1-C19007T 和 GSTP1-A105G 基因多态性与晚期食管癌顺铂为基础的化疗疗效之间的关系。共纳入 256 例经病理证实的晚期食管癌患者，给予顺铂联合 5-氟尿嘧啶方案化疗。对 241 例完成治疗的患者进行临床评估。结果显示，与 C/C 型患者相比，ERCC1-C8092A、A/C 或 A/A 型患者的缓解率更高（51.75%比 29.59%，P<0.01）。与 C/C 型患者相比，ERCC1-C8092A、A/C 或 A/A 型患者的无进展生存期更长（7.5 个月比 4.5 个月，P<0.0001）。C19007T 和 GSTP1-A105G 基因多态性与患者的缓解率和无进展生存期无显著相关性。结论：ERCC1-C8092A 基因多态性可能与晚期食管癌顺铂为基础的化疗疗效相关。需要进一步开展更大样本量的研究，为晚期食管癌的个体化化疗治疗提供依据。
